The Korean Journal of Applied Statistics (응용통계연구)

The Korean Statistical Society (한국통계학회)
권호 표지
DOI QR코드

DOI QR Code

Statistical Methods in Non-Inferiority Trials - A Focus on US FDA Guidelines -

  • Received : 2012.04.26
  • Accepted : 2012.06.18
  • Published : 2012.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

The effect of a new treatment is proven through the comparison of a new treatment with placebo; however, the number of parent non-inferiority trials tends to grow proportionally to the number of active controls. In a non-inferiority trial a new treatment is approved by proof that the new treatment is not inferior to an active control; however, both additional assumptions and historical trials are needed to show (through the comparison of the new treatment with the active control in a non-inferiority trial) that the new treatment is more efficacious than a putative placebo. The two different methods of using the historical data: frequentist principle method and meta-analytic method. This paper discusses the statistical methods and different Type I error rates obtained through the different methods employed.

Keywords

References

  1. Blackwelder, W. C. (1982). "Proving the null hypothesis" in clinical trials, Controlled Clinical Trials, 3, 345-353. https://doi.org/10.1016/0197-2456(82)90024-1
  2. D'Agostino, R. B., Massaro, J. M. and Sullivan, L. M. (2003). Non-inferiority trials: Design concepts and issues - the encounters of academic consultants in statistics, Statistics in Medicine, 22, 169-186.
  3. Fleming, T. R. (2008). Current issues in non-inferiority trials, Statistics in Medicine, 27, 317-332. https://doi.org/10.1002/sim.2855
  4. Hasselblad, V. and Kong, D. F. (2001). Statistical methods for comparison to placebo in active-control trials, Drug Information Journal, 35, 435-449. https://doi.org/10.1177/009286150103500212
  5. Holmgren, E. B. (1999). Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo in maintained, Journal of Biopharmaceutical Statistics, 9, 651-659. https://doi.org/10.1081/BIP-100101201
  6. Hung, H.-M., Wang, S.-J. and O'Neill, R. (2007). Issues with statistical risks for testing methods in noninferiority trial without a placebo arm, Journal of Biopharmaceutical Statistics, 17, 201-213. https://doi.org/10.1080/10543400601177343
  7. Hung, H. M., Wang, S. J. and O'Neill, R. (2009). Challenges and regulatory experiences with non-inferiority trial design without placebo arm, Biometrical Journal, 51, 324-334. https://doi.org/10.1002/bimj.200800219
  8. Hung, H.-M., Wang, S.-J.,Tsong, Y., Lawrence, J. and O'Neill, R. (2003). Some fundamental issues for noninferiority testing in active controlled trials, Statistics in Medicine, 22, 213-225.
  9. ICH E10 (2001). Choice of control group and related issues in clinical trials.
  10. Kang, S. H. (2010). Biostatistical Methods for New Drug Development, Freeacademy, Seoul.
  11. Kang, S. H. and Ryu, Y. (2011). The adjustment of the type I error rate in non-inferiority trials with - margin approach: Each of two different new drugs is approved with two independent trials with the same active control, Journal of Biopharmaceutical Statistics, 21, 498-510. https://doi.org/10.1080/10543406.2010.482683
  12. Kang, S. H. and Tsong, Y. (2010). Strength of evidence of non-inferiority trials - the adjustment of the type I error rate in non-inferiority trials with the synthesis method, Accepted by Statistics in Medicine, 29, 1477-1487.
  13. Leber, P. D. (1989). Hazards of inference: The active control interpretation, Epilepsia, 30, S57-S63. https://doi.org/10.1111/j.1528-1157.1989.tb05816.x
  14. Temple, R. and Ellenberg, S. S. (2000). Placebo-controlled trials and active- controlled trials in the evaluation of new treatment, part I: ethical and scientific issues, Annals of Interna Medicine, 133, 455-463. https://doi.org/10.7326/0003-4819-133-6-200009190-00014
  15. Tsong, Y. (2007). The utility of active-controlled noninferiority / equivalence trials in drug development, International Journal of Pharmaceutical Medicine, 21, 225-233. https://doi.org/10.2165/00124363-200721030-00005
  16. Tsong, Y., Wang, S.-J., Hung, H.-M. and Cui, L. (2003). Statistical issues on objective, design and analysis of noninferiority active-controlled clinical trial, Journal of Biopharmaceutical Statistics, 13, 29-41. https://doi.org/10.1081/BIP-120017724
  17. U.S. FDA (2010). Guidance for Industry: Non-Inferiority Clinical Trials (draft guidance)
  18. Wang, S.-J. and Hung, H.-M. (2002). Utility and pitfalls of some statistical methods in active controlled clinical trials, Controlled Clinical Trials, 23, 15-28. https://doi.org/10.1016/S0197-2456(01)00155-6
  19. Wang, S.-J. and Hung, H.-M. (2003). Assessing treatment efficacy in non-inferiority trials, Controlled Clinical Trials, 24, 147-155. https://doi.org/10.1016/S0197-2456(02)00304-5
  20. Wang, S. Y. and Kang, S. H. (2012). Strength of evidence of non-inferiority trials with the two confidence interval method with random margin, Journal of Biopharmaceutical Statistics, In press